Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The primary study objective is to determine the efficacy of pregabalin administered orally
for a period of 12 weeks in reducing risky drinking and symptoms of posttraumatic stress
disorder who have selected genotypes at the gamma-amino butyric acid transporter and receptor
genes. The secondary objective is to assess the safety and tolerability of pregabalin in
participants with alcohol use disorder and co-occurring posttraumatic stress disorder who
have selected genotypes at the gamma-amino butyric acid transporter and receptor genes. The
investigators will utilize a large and diverse sample of African-Americans that includes both
genders and individuals with different types of trauma. All participants will receive
standardized bi-weekly Brief Behavioral Compliance Enhancement Treatment (BBCET).
Phase:
Phase 3
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)